Cargando…

Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study

BACKGROUND: Cisplatin is a highly effective chemotherapeutic agent. However, acute kidney injury (AKI) limits its subsequent use, resulting in poor cancer prognosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to attenuate cisplatin-induced AKI in animal models, but the effect in hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwakura, Takamasa, Fukasawa, Hirotaka, Kitamura, Atsushi, Ishibuchi, Kento, Yasuda, Hideo, Furuya, Ryuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034844/
https://www.ncbi.nlm.nih.gov/pubmed/32084231
http://dx.doi.org/10.1371/journal.pone.0229377
_version_ 1783499954087526400
author Iwakura, Takamasa
Fukasawa, Hirotaka
Kitamura, Atsushi
Ishibuchi, Kento
Yasuda, Hideo
Furuya, Ryuichi
author_facet Iwakura, Takamasa
Fukasawa, Hirotaka
Kitamura, Atsushi
Ishibuchi, Kento
Yasuda, Hideo
Furuya, Ryuichi
author_sort Iwakura, Takamasa
collection PubMed
description BACKGROUND: Cisplatin is a highly effective chemotherapeutic agent. However, acute kidney injury (AKI) limits its subsequent use, resulting in poor cancer prognosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to attenuate cisplatin-induced AKI in animal models, but the effect in human patients remains to be clarified. We hypothesized that DPP-4 inhibitors can prevent cisplatin-induced AKI in diabetic-cancer patients. METHODS: We retrospectively reviewed all consecutive cancer patients who were treated with a first cycle of cisplatin-containing regimen between January 2011 and October 2019. We analysed data of diabetic-cancer patients treated with high-dose cisplatin (> 50 mg/m(2))-containing regimens. The change of estimated glomerular filtration rate (eGFR) within 2 weeks after cisplatin treatment was compared between the patients treated with DPP-4 inhibitors and those treated without DPP-4 inhibitors. RESULTS: A total of 455 patients were treated with cisplatin during the period. Of these, 34 patients were eligible for the analysis. The change of eGFR was significantly less in the patients treated with DPP-4 inhibitors, compared to those without DPP-4 inhibitors [the percentages of eGFR decline (mean ± SD) was 23.6 ± 20.3% vs 43.1± 20.1%, respectively; P = 0.010]. Furthermore, the incidence of AKI was significantly less in the patients treated with DPP-4 inhibitors (25% vs 64%, respectively; P = 0.026). CONCLUSIONS: DPP-4 inhibitors may decrease the risk of cisplatin-induced AKI in diabetic patients.
format Online
Article
Text
id pubmed-7034844
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70348442020-02-27 Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study Iwakura, Takamasa Fukasawa, Hirotaka Kitamura, Atsushi Ishibuchi, Kento Yasuda, Hideo Furuya, Ryuichi PLoS One Research Article BACKGROUND: Cisplatin is a highly effective chemotherapeutic agent. However, acute kidney injury (AKI) limits its subsequent use, resulting in poor cancer prognosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to attenuate cisplatin-induced AKI in animal models, but the effect in human patients remains to be clarified. We hypothesized that DPP-4 inhibitors can prevent cisplatin-induced AKI in diabetic-cancer patients. METHODS: We retrospectively reviewed all consecutive cancer patients who were treated with a first cycle of cisplatin-containing regimen between January 2011 and October 2019. We analysed data of diabetic-cancer patients treated with high-dose cisplatin (> 50 mg/m(2))-containing regimens. The change of estimated glomerular filtration rate (eGFR) within 2 weeks after cisplatin treatment was compared between the patients treated with DPP-4 inhibitors and those treated without DPP-4 inhibitors. RESULTS: A total of 455 patients were treated with cisplatin during the period. Of these, 34 patients were eligible for the analysis. The change of eGFR was significantly less in the patients treated with DPP-4 inhibitors, compared to those without DPP-4 inhibitors [the percentages of eGFR decline (mean ± SD) was 23.6 ± 20.3% vs 43.1± 20.1%, respectively; P = 0.010]. Furthermore, the incidence of AKI was significantly less in the patients treated with DPP-4 inhibitors (25% vs 64%, respectively; P = 0.026). CONCLUSIONS: DPP-4 inhibitors may decrease the risk of cisplatin-induced AKI in diabetic patients. Public Library of Science 2020-02-21 /pmc/articles/PMC7034844/ /pubmed/32084231 http://dx.doi.org/10.1371/journal.pone.0229377 Text en © 2020 Iwakura et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Iwakura, Takamasa
Fukasawa, Hirotaka
Kitamura, Atsushi
Ishibuchi, Kento
Yasuda, Hideo
Furuya, Ryuichi
Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
title Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
title_full Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
title_fullStr Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
title_full_unstemmed Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
title_short Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
title_sort effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034844/
https://www.ncbi.nlm.nih.gov/pubmed/32084231
http://dx.doi.org/10.1371/journal.pone.0229377
work_keys_str_mv AT iwakuratakamasa effectofdipeptidylpeptidase4inhibitorsoncisplatininducedacutenephrotoxicityincancerpatientswithdiabetesmellitusaretrospectivestudy
AT fukasawahirotaka effectofdipeptidylpeptidase4inhibitorsoncisplatininducedacutenephrotoxicityincancerpatientswithdiabetesmellitusaretrospectivestudy
AT kitamuraatsushi effectofdipeptidylpeptidase4inhibitorsoncisplatininducedacutenephrotoxicityincancerpatientswithdiabetesmellitusaretrospectivestudy
AT ishibuchikento effectofdipeptidylpeptidase4inhibitorsoncisplatininducedacutenephrotoxicityincancerpatientswithdiabetesmellitusaretrospectivestudy
AT yasudahideo effectofdipeptidylpeptidase4inhibitorsoncisplatininducedacutenephrotoxicityincancerpatientswithdiabetesmellitusaretrospectivestudy
AT furuyaryuichi effectofdipeptidylpeptidase4inhibitorsoncisplatininducedacutenephrotoxicityincancerpatientswithdiabetesmellitusaretrospectivestudy